Market Place
Market Place
Post Enquiry
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
Drop in Covid sales, trial failures, restructuring trigger steep rise in layoffs in Q1 2023
Since 2022, layoffs have become commonplace. The ongoing global banking crisis, coupled with pre-exi
